Related Experiment Video
Updated: May 27, 2025
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Predictive value of platelet function assays in traumatic brain injury patients on antiplatelet therapy
Nijmeh Alsaadi1, Reem Younes, Jack R Killinger
1From the Trauma and Transfusion Medicine Research Center (N.A., R.Y., J.R.K., L.H., A.S., M.Z., D.M.D., A. Abdullah, A. Arivudainambi, R.K., E.P.M., P.L., P.C.S., J.L.S., S.M.S., M.D.N.); and Department of Surgery (N.A., R.Y., J.R.K., L.H., L.E.V., A.S., M.Z., D.M.D., A. Abdullah, E.P.M., P.L., J.L.S., S.M.S., M.D.N.), Department of Neurosurgery (A.M.P., P.M., O.R., A.F., T.H., A.G.A., D.O.), School of Public Health (S.R.W., J.F.L.), Department of Emergency Medicine (F.X.G.), and Department of Bioengineering (S.M.S.), University of Pittsburgh, Pittsburgh, Pennsylvania.
Introduction:
Traumatic brain injury (TBI) patients on antiplatelet therapy face higher mortality because of impaired platelet function, which may be treated by platelet transfusion. The value of testing platelet function in this cohort remains controversial. We aimed to evaluate the relationship between platelet function assays and outcomes in TBI patients on antiplatelet therapy receiving platelet transfusions. We hypothesized that the magnitude of change in platelet assay performance following a transfusion would predict meaningful clinical outcomes.
Methods:
A cohort of patients, aged 18 to 89 years, with a history of preinjury antiplatelet therapy or who required platelet transfusion, and who were deemed at risk for neurosurgical intervention, was selected from a prospective randomized controlled trial of platelet transfusion for TBI. Pre- and posttransfusion blood samples were drawn. Platelet hemostatic function assays (PHFAs) included thromboelastography with platelet mapping (TEG-PM) and VerifyNow. Logistic regression models assessed the association of temporal assay results with 30-day all-cause mortality, need for craniotomy, and initial and follow-up Rotterdam scores.
Results:
Data from 94 TBI patients (43% female) with a median age of 76 years were analyzed. The 30-day mortality rate was 14%. VerifyNow aspirin assay was able to capture increases in platelet function following a platelet transfusion in patients on aspirin (significant positive Δ = 65 aspirin response units, p < 0.001). Thromboelastography with platelet mapping parameters detected improved platelet function following transfusion, although the absolute value of changes was minimal. Thromboelastography with platelet mapping parameters predicted important clinical outcomes on logistic regression, although no significant associations with clinical outcomes were identified by the change in PHFA after transfusion or after adjusting for multiple comparisons.
Conclusion:
Higher absolute pre- and posttransfusion values of TEG-PM were associated with decreased mortality, decreased need for neurosurgical intervention, and decreased risk of progression of hemorrhage in TBI patients taking antiplatelet agents, although neither the change in TEG-PM after transfusion nor any other PHFA value predicted outcomes.
Level Of Evidence:
Prognostic and Epidemiological; Level II.
Related Concept Videos
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:18Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...